Proteasome inhibition for antibody-mediated rejection

Current Opinion in Organ Transplantation

Volumn 14, Issue 6, 2009, Pages 662-666

  Everly, Jason J ^a   Walsh, R Carlin ^a   Alloway, Rita R ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bortezomib; Humoral rejection; Proteasome inhibition

Indexed keywords

BORTEZOMIB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB;

ACUTE GRAFT REJECTION; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; BIOCHEMISTRY; CELL POPULATION; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS; HISTOLOGY; HUMAN; HUMORAL IMMUNITY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MANTLE CELL LYMPHOMA; MITOSIS; MULTIPLE MYELOMA; ORGAN TRANSPLANTATION; PARESTHESIA; PLASMA CELL; PLEIOTROPY; POLYARTHRITIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES; BORONIC ACIDS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; KIDNEY TRANSPLANTATION; PLASMA CELLS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 74349101176     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328330f304     Document Type: Review

References (29)

1. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7:402-407.
2. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9:1-9.
3. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86:1754-1761.
4. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9:201-209.
5. Lee DH, Goldberg AL. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem 1996; 271:27280-27284.
6. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78:761-771.
7. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426:895-899.
8. Jesenberger V, Jentsch S. Deadly encounter: Ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 2002; 3:112-121.
9. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002; 82:965-980.
10. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 2002; 1:337-341.
11. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4:192-201.
12. Wojcikiewicz RJ. Regulated ubiquitination of proteins in GPCR-initiated signaling pathways. Trends Pharmacol Sci 2004; 25:35-41.
13. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHCclass-I-mediated antigen presentation. Curr Opin Immunol 2004; 16:76-81.
14. Bowerman B, Kurz T. Degrade to create: Developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development 2006; 133:773-784.
15. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: A new antiinflammatory strategy. J Mol Med 2003; 81:235-245.
16. Yew PR. Ubiquitin-mediated proteolysis of vertebrate G1-and S-phase regulators. J Cell Physiol 2001; 187:1-10.
17. Gilmore TD. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 2006; 25:6680-6684.
18. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000; 150:887-894.
19. Yoshida H, Matsui T, Yamamoto A, et al. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107:881-891.
20. Mathai JP, Germain M, Shore GC. BH3-only BIK regulates BAX,BAK-dependent release of Ca2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. J Biol Chem 2005; 280:23829-23836.
21. Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 2009; 50:974-984.
22. Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7:2298-2307.
23. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107:4907-4916.
24. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002; 2:904-912.
25. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in Streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998; 95:15671-15676.
26. Vanderlugt CL, Rahbe SM, Elliott PJ, et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000; 14:205-211.
27. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-755.
28. Walsh RC, Everly JJ, Everly MJ, et al. Bortezomib treatment for refractory acute humoral rejection: Intermediate results. Am J Transpl 2009; 9 (s2):189-383. [Abstract 462].
29. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87:1555-1561.